within Pharmacolibrary.Drugs.ATC.L;

model L03AB11
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0016666666666666668,
    adminDuration  = 600,
    adminMass      = 180 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L03AB11</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Peginterferon alfa-2a is a pegylated form of interferon alfa-2a, an immunomodulatory drug used primarily in the treatment of chronic hepatitis B and C infections. By attaching polyethylene glycol (PEG) to interferon alfa-2a, the drug has an extended half-life, allowing for less frequent dosing. Peginterferon alfa-2a is approved and widely used for antiviral therapy, though its use has decreased with the advent of newer direct-acting antivirals for hepatitis C.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adults with chronic hepatitis C, both male and female, under standard clinical dosing.</p><h4>References</h4><ol><li><p>Sulkowski, M, et al., &amp; Yalamanchili, S (2005). Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. <i>Clinical pharmacology and therapeutics</i> 77(3) 214–224. DOI:<a href=&quot;https://doi.org/10.1016/j.clpt.2004.09.008&quot;>10.1016/j.clpt.2004.09.008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15735615/&quot;>https://pubmed.ncbi.nlm.nih.gov/15735615</a></p></li><li><p>Fülöp, B, et al., &amp; Berg, T (2015). Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. <i>Liver international : official journal of the International Association for the Study of the Liver</i> 35(10) 2275–2284. DOI:<a href=&quot;https://doi.org/10.1111/liv.12832&quot;>10.1111/liv.12832</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25801095/&quot;>https://pubmed.ncbi.nlm.nih.gov/25801095</a></p></li><li><p>Elsadek, NE, et al., &amp; Ishida, T (2020). Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice. <i>Molecular pharmaceutics</i> 17(8) 2964–2970. DOI:<a href=&quot;https://doi.org/10.1021/acs.molpharmaceut.0c00366&quot;>10.1021/acs.molpharmaceut.0c00366</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32519877/&quot;>https://pubmed.ncbi.nlm.nih.gov/32519877</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L03AB11;
